Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10582MR)

This product GTTS-WQ10582MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10582MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1640MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ10659MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ7633MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ12111MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ6492MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ3120MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ12253MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ8963MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW